|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | The spatial distribution of visual attention in developmental dyslexia显示文摘 | Facoetti A Lorusso ML Paganoni P | | 0，，： | 1 |
| 2 | Targeting the Hedgehog path- way in cancer 显示文摘 | Gupta S Takebe N Lorusso P | 2010 | Ther Adv Med Oncol2010，2，4： | 1 |
| 3 | Continuous administration of ZD1839 (Iressa), a novel oral epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), in patients with five selected tumor types:Evidence of activity and good tolerability显示文摘 | Baselga J Herbst R LoRusso P | 2000 | Proc Am Soc Clin Oncol2000，19，17： | 1 |
| 4 | Randomized clinical trial of mitomyein-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer 显示文摘 | Poplin Ea Lorusso P Lokieh JJ | 1994 | Cancer Chemother Pharmaeol1994，33，5： | 1 |
| 5 | Erlotinib therapy for central nervous system hemangioblastomatosis associated with van Hippel-Lindau disease : a case report 显示文摘 | Rogers LR LoRusso P Nadler P | 2011 | J Neurooncol2011，101，： | 1 |
| 6 | Targeting the Hedgehog path- way in cancer 显示文摘 | Gupta S Takebe N Lorusso P | 2010 | Ther Adv Med Oncol2010，2，4： | 1 |
| 7 | Tremelimumab in combination with exemestane in patients with advanced breast cancer and treatment-associated modulation of inducible costimulator expression on patient T cells 显示文摘 | Vonderheide R H LoRusso P M Khalil M | 2010 | Cancer Res2010，16，13： | 1 |
| 8 | Dermatologic side effects associated with gefitinib therapy:clinical experience and management显示文摘 | HERBST R S LORUSSO P M PURDOM M | 2003 | Clin Lung Cancer2003，4，6： | 1 |
| 9 | Haemodynamic effects of intravenous growth hormone kin congestive heart failure显示文摘 | Volterrani M Desenzani P Lorusso R | 1997 | Lancet1997，349，4： | 1 |
| 10 | Improvements in quality of life and disease-related symptoms in phase Ⅰ trials of the selective oral epidermal growth factor receptor tyrosine inhibitor ZD1839 in non-small-cell lung cancer and other solid tumors显示文摘 | Lorusso P M Herbst R S Rischin D | 2003 | Clin Cancer Res2003，9，6： | 1 |
| 11 | Targeting the Hedgehog pathway in cancer 显示文摘 | Gupta S Takebe N Lorusso P | 2010 | Ther Adv Med Oncol2010，2，4： | 1 |
| 12 | A phase II study of trastu- zumab emtansine in patients with human epidermal growth factor receptor 2 - positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine显示文摘 | Krop I E LoRusso P Miller K D | 2012 | J Clin Oncol2012，30，26： | 1 |
| 13 | A Phase 1 dose-es- calation study of the safety, pharmacokinetics and pharmacodynamics of XL765 (SAR245409), a PI3K/ TORC1/TORC2 inhibitor administered orally to pa- tients with advanced malignancies显示文摘 | Brana I LoRusso P Baselga J | 2010 | J Clin Oncol2010，28，15： | 1 |
| 14 | Vasoactive intestinal polypeptide immunoreactivity in the human cerebellum:qualitative and quantitative analyses显示文摘 | Benagiano V Flace P Lorusso L | | 0，，03： | 1 |
| 15 | Targeting the Hedgehog pathway in cancer显示文摘 | Gupta S Takebe N Lorusso P | 2010 | Ther Adv Med Oncol2010，2，4： | 1 |
| 16 | A Phase Ib study evaluating MNRP1685A, a fully human anti-NRP1 mono- clonal antibody, in combination with bevacizumab and paelitaxel in patients with advanced solid tumors 显示文摘 | Patnaik A LoRusso P M Messersmith W A | 2014 | Cancer Chemother Phar- macol2014，73，5： | 1 |
| 17 | A phase 1-2 clinical study of a second generation oral MEK inhibitor, PD0325901 in patients with advanced cancer 显示文摘 | Lorusso P Krishnamurthi S Rinehart J R | 2005 | J Clin Oncol ( Meeting Abstact)2005，23，： | 1 |
| 18 | Improvements in quality of life and disease--related symptoms in phase I trials of the selective oral epidermal growth factor receptor tyrosine kinases inhibitor ZD1839 in non small cell lung cancer and other solid tumor显示文摘 | Lorusso P M Herbst R S Rischin D | 2003 | Clin Cancer Res2003，9，6： | 1 |
| 19 | Phase 1, open-label studyof MEDI-547 in patients with relapsed or refractory solid tumors 显示文摘 | Annunziata CM Kohn EC Lorusso P | 2013 | Invest New Drugs2013，31，1： | 1 |
| 20 | A phase I study of MK-5108, an oral Aurora A kinase inhibitor, in both monotherapy and in combination with docetaxel in patients with advanced solid tumors 显示文摘 | MINTON S E LORUSSO P LOCKHART A C | 2010 | J Clin Onco12010，，13： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员